Tumor-associated lymphocytes and macrophages are related to stromal elastosis and vascular invasion in breast cancer.


Journal

The journal of pathology. Clinical research
ISSN: 2056-4538
Titre abrégé: J Pathol Clin Res
Pays: England
ID NLM: 101658534

Informations de publication

Date de publication:
09 2021
Historique:
revised: 25 03 2021
received: 13 12 2020
accepted: 05 05 2021
pubmed: 3 6 2021
medline: 16 2 2022
entrez: 2 6 2021
Statut: ppublish

Résumé

The tumor microenvironment plays a critical role in breast cancer progression. Here, we investigated tumor-infiltrating lymphocytes (TILs) and associations with macrophage numbers, tumor stromal elastosis, vascular invasion, and tumor detection mode. We performed a population-based retrospective study using data from The Norwegian Breast Cancer Screening Program in Vestfold County (2004-2009), including 200 screen-detected and 82 interval cancers. The number of TILs (CD45+, CD3+, CD4+, CD8+, and FOXP3+) and tumor-associated macrophages (CD163+) was counted using immunohistochemistry on tissue microarray slides. Lymphatic and blood vessel invasion (LVI and BVI) were recorded using D2-40 and CD31 staining, and the amount of elastosis (high/low) was determined on regular HE-stained slides. High numbers of all TIL subsets were associated with LVI (p ≤ 0.04 for all), and high counts of several TIL subgroups (CD8+, CD45+, and FOXP3+) were associated with BVI (p ≤ 0.04 for all). Increased levels of all TIL subsets, except CD4+, were associated with estrogen receptor-negative tumors (p < 0.001) and high tumor cell proliferation by Ki67 (p < 0.001). Furthermore, high levels of all TIL subsets were associated with high macrophage counts (p < 0.001) and low-grade stromal elastosis (p ≤ 0.02). High counts of CD3+, CD8+, and FOXP3+ TILs were associated with interval detected tumors (p ≤ 0.04 for all). Finally, in the luminal A subgroup, high levels of CD3+ and FOXP3+ TILs were associated with shorter recurrence-free survival, and high counts of FOXP3+ were linked to reduced breast cancer-specific survival. In conclusion, higher levels of different TIL subsets were associated with stromal features such as high macrophage counts (CD163+), presence of vascular invasion, absence of stromal elastosis, as well as increased tumor cell proliferation and interval detection mode. Our findings support a link between immune cells and vascular invasion in more aggressive breast cancer. Notably, presence of TIL subsets showed prognostic value within the luminal A category.

Identifiants

pubmed: 34076969
doi: 10.1002/cjp2.226
pmc: PMC8363927
doi:

Substances chimiques

Antigens, CD 0
Biomarkers, Tumor 0
Ki-67 Antigen 0
Elastin 9007-58-3
Receptor, ErbB-2 EC 2.7.10.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

517-527

Informations de copyright

© 2021 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland & John Wiley & Sons, Ltd.

Références

Integr Biol (Camb). 2015 Oct;7(10):1120-34
pubmed: 25959051
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Clin Cancer Res. 2006 Feb 15;12(4):1168-74
pubmed: 16489070
Breast Cancer Res. 2011;13(6):227
pubmed: 22078026
PLoS One. 2014 Dec 12;9(12):e115103
pubmed: 25501357
J Clin Oncol. 2011 May 20;29(15):1949-55
pubmed: 21483002
Acta Oncol. 2007;46(6):792-7
pubmed: 17653902
Pathologe. 2018 Nov;39(6):520-531
pubmed: 30327858
Breast Cancer Res Treat. 2011 Dec;130(3):725-34
pubmed: 21892702
Eur J Surg Oncol. 2017 Jul;43(7):1258-1264
pubmed: 28214052
PLoS One. 2014 Nov 06;9(11):e112121
pubmed: 25375149
J Clin Oncol. 2014 Sep 20;32(27):2959-66
pubmed: 25071121
Semin Cancer Biol. 2012 Oct;22(5-6):455-61
pubmed: 22627188
Curr Mol Biol Rep. 2017 Dec;3(4):218-229
pubmed: 29430386
Diagn Pathol. 2014 Dec 19;9:230
pubmed: 25522915
Am J Clin Pathol. 2019 Oct 7;152(5):656-665
pubmed: 31305879
Semin Cancer Biol. 2018 Oct;52(Pt 2):16-25
pubmed: 29024776
Oncol Lett. 2019 Feb;17(2):2177-2186
pubmed: 30675282
J Med Screen. 2016 Jun;23(2):89-97
pubmed: 26582492
Ann Oncol. 2013 Sep;24(9):2206-23
pubmed: 23917950
Expert Opin Biol Ther. 2008 Dec;8(12):1897-920
pubmed: 18990077
J Clin Oncol. 2020 Apr 20;38(12):1346-1366
pubmed: 31928404
Front Oncol. 2017 Aug 03;7:156
pubmed: 28824872
Crit Rev Oncol Hematol. 2014 Feb;89(2):231-41
pubmed: 24075309
Oncotarget. 2015 Oct 27;6(33):34758-73
pubmed: 26416449
J Immunother Cancer. 2016 Oct 18;4:59
pubmed: 27777769
J R Coll Surg Edinb. 1972 Sep;17(5):315-20
pubmed: 5076399
Breast Cancer. 2017 Jan;24(1):3-15
pubmed: 27138387
Cancer Res. 2001 Mar 1;61(5):2256-60
pubmed: 11280795
BMJ. 2009 Jul 09;339:b2587
pubmed: 19589821
Am J Transl Res. 2019 Aug 15;11(8):5039-5053
pubmed: 31497220
Breast Cancer Res. 2021 Feb 18;23(1):27
pubmed: 33602289
Breast Cancer (Auckl). 2017 Sep 25;11:1178223417731565
pubmed: 28979132
J Natl Cancer Inst. 2011 Apr 6;103(7):585-97
pubmed: 21350218
Br J Cancer. 2009 Oct 20;101(8):1338-44
pubmed: 19773756
Future Oncol. 2019 Apr;15(11):1193-1196
pubmed: 30880457
Exp Cell Res. 2010 May 1;316(8):1324-31
pubmed: 20211171
BMC Cancer. 2016 Aug 26;16:687
pubmed: 27566250
J Clin Oncol. 2010 Oct 10;28(29):4531-8
pubmed: 20516428
Cancer Treat Rev. 2018 Nov;70:178-189
pubmed: 30227299
Br J Cancer. 2013 Sep 17;109(6):1676-84
pubmed: 23982600
Lancet Oncol. 2018 Jan;19(1):40-50
pubmed: 29233559
Breast Cancer Res. 2019 Aug 7;21(1):90
pubmed: 31391067
BMC Med. 2015 Aug 24;13:202
pubmed: 26300242
Am J Clin Oncol. 2013 Jun;36(3):224-31
pubmed: 22495453
Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
FASEB J. 1999 Oct;13(13):1743-50
pubmed: 10506577
Clin Transl Oncol. 2016 May;18(5):497-506
pubmed: 26459255
Histopathology. 1991 Nov;19(5):403-10
pubmed: 1757079
Neoplasma. 2016;63(5):789-98
pubmed: 27468884
J Clin Pathol. 1997 Aug;50(8):669-73
pubmed: 9301551
Hum Pathol. 2017 Nov;69:72-80
pubmed: 28923419
J Clin Pathol. 2017 Apr;70(4):313-319
pubmed: 27612505
Clin Transl Oncol. 2016 Mar;18(3):251-8
pubmed: 26264497
Cancer Treat Rev. 2012 Dec;38(8):943-55
pubmed: 22651904
Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2796-801
pubmed: 21825174
Breast Cancer Res. 2014 Sep 06;16(5):432
pubmed: 25193543
Breast Care (Basel). 2016 Apr;11(2):96-100
pubmed: 27239170
JAMA Oncol. 2017 Nov 9;3(11):e172085
pubmed: 28750133
Cancer Biol Med. 2017 Feb;14(1):1-8
pubmed: 28443199
Lancet Oncol. 2014 Oct;15(11):e493-503
pubmed: 25281468
Breast Cancer Res. 2012 Mar 15;14(2):R48
pubmed: 22420471
Breast Cancer Res. 2013 May 16;15(3):R41
pubmed: 23680223

Auteurs

Ying Chen (Y)

Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen, Bergen, Norway.
Department of Pathology, Vestfold Hospital, Tønsberg, Norway.
Department of Pathology, Oslo University Hospital, Oslo, Norway.

Tor Audun Klingen (TA)

Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen, Bergen, Norway.
Department of Pathology, Vestfold Hospital, Tønsberg, Norway.

Hans Aas (H)

Department of Surgery, Vestfold Hospital, Tønsberg, Norway.

Elisabeth Wik (E)

Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen, Bergen, Norway.
Department of Pathology, Haukeland University Hospital, Bergen, Norway.

Lars A Akslen (LA)

Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen, Bergen, Norway.
Department of Pathology, Haukeland University Hospital, Bergen, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH